BioCentury
ARTICLE | Company News

RegeneRx deal

January 2, 2012 8:00 AM UTC

RegeneRx said that it is in "licensing and other product-related discussions" with four partners for RGN-259. RegeneRx said it will take cost-cutting steps to save cash until a deal is closed, and that it will provide more details after Jan. 1. The company plans to close a deal by Jan. 31. At Sept. 30, 2011, RegeneRx had $524,459 in cash and a nine-month operating loss of $5.1 million. ...